Original Article
Cost-Effectiveness and Cost-Utility Analysis of Ingenol Mebutate Versus Diclofenac 3% and Imiquimod 5% in the Treatment of Actinic Keratosis in Spain
Análisis de coste-efectividad y coste-utilidad de ingenol mebutato versus diclofenaco 3% e imiquimod 5% en el tratamiento de la queratosis actínica en España
I. Elíasa, N. Ortega-Joaquína, P. de la Cuevab, L.J. del Pozoc, D. Moreno-Ramírezd, A. Boadae, M. Aguilarf, A. Miradag, E. Mosquerag, C. Gibbonsh, I. Oyagüeza,
Autor para correspondencia
a Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
b Departamento de Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain
c Departamento de Dermatología, Hospital Universitario Son Espases, Mallorca, Spain
d Departamento de Dermatología, Hospital Universitario Virgen de la Macarena, Sevilla, Spain
e Departamento de Dermatología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
f Departamento de Dermatología, Hospital Costa del Sol, Marbella, Málaga, Spain
g Laboratorios LEO Pharma, S. A., Barcelona, Spain
h LEO Pharma, Berkshire, Reino Unido
Leído
6925
Vecesse ha leído el artículo
2383
Total PDF
4542
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 6 | 47 | 8 | 55 |
| 2025 5 | 152 | 40 | 192 |
| 2025 4 | 146 | 32 | 178 |
| 2025 3 | 129 | 23 | 152 |
| 2025 2 | 189 | 33 | 222 |
| 2025 1 | 94 | 24 | 118 |
| 2024 12 | 78 | 23 | 101 |
| 2024 11 | 88 | 62 | 150 |
| 2024 10 | 76 | 40 | 116 |
| 2024 9 | 63 | 23 | 86 |
| 2024 8 | 105 | 47 | 152 |
| 2024 7 | 106 | 32 | 138 |
| 2024 6 | 95 | 33 | 128 |
| 2024 5 | 90 | 33 | 123 |
| 2024 4 | 101 | 31 | 132 |
| 2024 3 | 98 | 27 | 125 |
| 2024 2 | 83 | 30 | 113 |
| 2024 1 | 81 | 35 | 116 |
| 2023 12 | 74 | 15 | 89 |
| 2023 11 | 81 | 26 | 107 |
| 2023 10 | 123 | 23 | 146 |
| 2023 9 | 71 | 26 | 97 |
| 2023 8 | 33 | 12 | 45 |
| 2023 7 | 41 | 46 | 87 |
| 2023 6 | 27 | 13 | 40 |
| 2023 5 | 47 | 23 | 70 |
| 2023 4 | 38 | 29 | 67 |
| 2023 3 | 50 | 23 | 73 |
| 2023 2 | 35 | 28 | 63 |
| 2022 1 | 40 | 24 | 64 |
| 2022 12 | 69 | 33 | 102 |
| 2022 11 | 44 | 24 | 68 |
| 2022 10 | 27 | 33 | 60 |
| 2022 9 | 29 | 42 | 71 |
| 2022 8 | 24 | 32 | 56 |
| 2022 7 | 28 | 56 | 84 |
| 2022 6 | 20 | 26 | 46 |
| 2022 5 | 51 | 35 | 86 |
| 2022 4 | 47 | 35 | 82 |
| 2022 3 | 53 | 65 | 118 |
| 2022 2 | 44 | 64 | 108 |
| 2021 1 | 34 | 60 | 94 |
| 2021 12 | 41 | 48 | 89 |
| 2021 11 | 49 | 47 | 96 |
| 2021 10 | 60 | 57 | 117 |
| 2021 9 | 41 | 42 | 83 |
| 2021 8 | 51 | 32 | 83 |
| 2021 7 | 34 | 36 | 70 |
| 2021 6 | 67 | 42 | 109 |
| 2021 5 | 40 | 56 | 96 |
| 2021 4 | 114 | 80 | 194 |
| 2021 3 | 68 | 33 | 101 |
| 2021 2 | 43 | 37 | 80 |
| 2020 1 | 35 | 21 | 56 |
| 2020 12 | 62 | 21 | 83 |
| 2020 11 | 24 | 32 | 56 |
| 2020 10 | 31 | 15 | 46 |
| 2020 9 | 40 | 17 | 57 |
| 2020 8 | 20 | 23 | 43 |
| 2020 7 | 26 | 20 | 46 |
| 2020 6 | 41 | 41 | 82 |
| 2020 5 | 36 | 16 | 52 |
| 2020 4 | 22 | 21 | 43 |
| 2020 3 | 27 | 23 | 50 |
| 2020 2 | 5 | 0 | 5 |
| 2019 4 | 5 | 8 | 13 |
| 2019 3 | 0 | 4 | 4 |
| 2019 2 | 1 | 0 | 1 |
| 2019 1 | 1 | 0 | 1 |
| 2018 12 | 3 | 0 | 3 |
| 2018 11 | 1 | 0 | 1 |
| 2018 10 | 1 | 0 | 1 |
| 2018 9 | 5 | 0 | 5 |
| 2018 2 | 23 | 5 | 28 |
| 2018 1 | 40 | 12 | 52 |
| 2017 12 | 41 | 10 | 51 |
| 2017 11 | 46 | 12 | 58 |
| 2017 10 | 35 | 12 | 47 |
| 2017 9 | 32 | 15 | 47 |
| 2017 8 | 30 | 15 | 45 |
| 2017 7 | 26 | 9 | 35 |
| 2017 6 | 47 | 11 | 58 |
| 2017 5 | 34 | 18 | 52 |
| 2017 4 | 39 | 14 | 53 |
| 2017 3 | 28 | 14 | 42 |
| 2017 2 | 15 | 19 | 34 |
| 2016 1 | 22 | 8 | 30 |
| 2016 12 | 55 | 19 | 74 |
| 2016 11 | 48 | 23 | 71 |
| 2016 10 | 33 | 22 | 55 |
| 2016 7 | 3 | 4 | 7 |
Mostrar todo
